vs

Side-by-side financial comparison of PUMA BIOTECHNOLOGY, INC. (PBYI) and WEYCO GROUP INC (WEYS). Click either name above to swap in a different company.

WEYCO GROUP INC is the larger business by last-quarter revenue ($76.8M vs $75.5M, roughly 1.0× PUMA BIOTECHNOLOGY, INC.). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs -4.6%). WEYCO GROUP INC produced more free cash flow last quarter ($23.1M vs $14.4M). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs 3.6%).

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

Weyco Group is an American footwear company that designs, markets and distributes brand names including Florsheim, Nunn Bush, Stacy Adams, BOGS, Rafters and Umi. The company, which focuses on North American wholesale and retail distribution, has been assembled by a series of acquisitions.

PBYI vs WEYS — Head-to-Head

Bigger by revenue
WEYS
WEYS
1.0× larger
WEYS
$76.8M
$75.5M
PBYI
Growing faster (revenue YoY)
PBYI
PBYI
+32.3% gap
PBYI
27.7%
-4.6%
WEYS
More free cash flow
WEYS
WEYS
$8.8M more FCF
WEYS
$23.1M
$14.4M
PBYI
Faster 2-yr revenue CAGR
PBYI
PBYI
Annualised
PBYI
31.3%
3.6%
WEYS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
PBYI
PBYI
WEYS
WEYS
Revenue
$75.5M
$76.8M
Net Profit
$8.7M
Gross Margin
69.3%
44.1%
Operating Margin
22.7%
13.3%
Net Margin
11.3%
Revenue YoY
27.7%
-4.6%
Net Profit YoY
-13.1%
EPS (diluted)
$0.26
$0.91

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PBYI
PBYI
WEYS
WEYS
Q4 25
$75.5M
$76.8M
Q3 25
$54.5M
$73.1M
Q2 25
$52.4M
$58.2M
Q1 25
$46.0M
$68.0M
Q4 24
$59.1M
$80.5M
Q3 24
$80.5M
$74.3M
Q2 24
$47.1M
$63.9M
Q1 24
$43.8M
$71.6M
Net Profit
PBYI
PBYI
WEYS
WEYS
Q4 25
$8.7M
Q3 25
$8.8M
$6.6M
Q2 25
$5.9M
$2.3M
Q1 25
$3.0M
$5.5M
Q4 24
$10.0M
Q3 24
$20.3M
$8.1M
Q2 24
$-4.5M
$5.6M
Q1 24
$-4.8M
$6.7M
Gross Margin
PBYI
PBYI
WEYS
WEYS
Q4 25
69.3%
44.1%
Q3 25
77.7%
40.7%
Q2 25
76.5%
43.3%
Q1 25
77.1%
44.6%
Q4 24
76.4%
47.9%
Q3 24
63.9%
44.3%
Q2 24
77.4%
43.9%
Q1 24
75.5%
44.7%
Operating Margin
PBYI
PBYI
WEYS
WEYS
Q4 25
22.7%
13.3%
Q3 25
17.6%
11.0%
Q2 25
12.7%
6.7%
Q1 25
8.7%
10.3%
Q4 24
22.6%
14.3%
Q3 24
27.4%
13.7%
Q2 24
-4.6%
10.4%
Q1 24
-5.3%
11.5%
Net Margin
PBYI
PBYI
WEYS
WEYS
Q4 25
11.3%
Q3 25
16.2%
9.0%
Q2 25
11.2%
3.9%
Q1 25
6.5%
8.1%
Q4 24
12.4%
Q3 24
25.2%
10.8%
Q2 24
-9.6%
8.8%
Q1 24
-11.0%
9.3%
EPS (diluted)
PBYI
PBYI
WEYS
WEYS
Q4 25
$0.26
$0.91
Q3 25
$0.17
$0.69
Q2 25
$0.12
$0.24
Q1 25
$0.06
$0.57
Q4 24
$0.40
$1.04
Q3 24
$0.41
$0.84
Q2 24
$-0.09
$0.59
Q1 24
$-0.10
$0.69

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PBYI
PBYI
WEYS
WEYS
Cash + ST InvestmentsLiquidity on hand
$97.5M
$96.0M
Total DebtLower is stronger
$22.7M
Stockholders' EquityBook value
$130.3M
$239.6M
Total Assets
$216.3M
$319.7M
Debt / EquityLower = less leverage
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PBYI
PBYI
WEYS
WEYS
Q4 25
$97.5M
$96.0M
Q3 25
$94.4M
$72.9M
Q2 25
$96.0M
$77.4M
Q1 25
$93.2M
$71.5M
Q4 24
$101.0M
$71.0M
Q3 24
$96.7M
$75.5M
Q2 24
$96.8M
$78.4M
Q1 24
$107.2M
$78.3M
Total Debt
PBYI
PBYI
WEYS
WEYS
Q4 25
$22.7M
Q3 25
$34.0M
Q2 25
$45.3M
Q1 25
$56.7M
Q4 24
$68.0M
Q3 24
$79.3M
Q2 24
$90.7M
Q1 24
$102.0M
Stockholders' Equity
PBYI
PBYI
WEYS
WEYS
Q4 25
$130.3M
$239.6M
Q3 25
$115.3M
$251.3M
Q2 25
$104.7M
$248.1M
Q1 25
$97.1M
$248.6M
Q4 24
$92.1M
$245.6M
Q3 24
$71.1M
$258.1M
Q2 24
$48.5M
$251.2M
Q1 24
$51.0M
$248.1M
Total Assets
PBYI
PBYI
WEYS
WEYS
Q4 25
$216.3M
$319.7M
Q3 25
$202.9M
$304.0M
Q2 25
$194.9M
$300.9M
Q1 25
$196.2M
$299.3M
Q4 24
$213.3M
$324.1M
Q3 24
$220.7M
$314.7M
Q2 24
$205.0M
$303.8M
Q1 24
$214.1M
$303.3M
Debt / Equity
PBYI
PBYI
WEYS
WEYS
Q4 25
0.17×
Q3 25
0.30×
Q2 25
0.43×
Q1 25
0.58×
Q4 24
0.74×
Q3 24
1.12×
Q2 24
1.87×
Q1 24
2.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PBYI
PBYI
WEYS
WEYS
Operating Cash FlowLast quarter
$14.4M
$24.0M
Free Cash FlowOCF − Capex
$14.4M
$23.1M
FCF MarginFCF / Revenue
19.1%
30.1%
Capex IntensityCapex / Revenue
0.0%
1.1%
Cash ConversionOCF / Net Profit
2.76×
TTM Free Cash FlowTrailing 4 quarters
$41.7M
$35.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PBYI
PBYI
WEYS
WEYS
Q4 25
$14.4M
$24.0M
Q3 25
$9.7M
$-1.1M
Q2 25
$14.1M
$10.2M
Q1 25
$3.6M
$4.1M
Q4 24
$15.6M
$20.4M
Q3 24
$11.0M
$-374.0K
Q2 24
$1.0M
$3.3M
Q1 24
$11.2M
$14.3M
Free Cash Flow
PBYI
PBYI
WEYS
WEYS
Q4 25
$14.4M
$23.1M
Q3 25
$9.7M
$-1.3M
Q2 25
$14.1M
$10.0M
Q1 25
$3.6M
$3.7M
Q4 24
$15.6M
$19.9M
Q3 24
$11.0M
$-930.0K
Q2 24
$1.0M
$3.2M
Q1 24
$14.2M
FCF Margin
PBYI
PBYI
WEYS
WEYS
Q4 25
19.1%
30.1%
Q3 25
17.7%
-1.8%
Q2 25
26.8%
17.1%
Q1 25
7.7%
5.5%
Q4 24
26.4%
24.8%
Q3 24
13.7%
-1.3%
Q2 24
2.1%
4.9%
Q1 24
19.8%
Capex Intensity
PBYI
PBYI
WEYS
WEYS
Q4 25
0.0%
1.1%
Q3 25
0.0%
0.3%
Q2 25
0.0%
0.4%
Q1 25
0.1%
0.6%
Q4 24
0.0%
0.6%
Q3 24
0.0%
0.7%
Q2 24
0.0%
0.3%
Q1 24
0.0%
0.2%
Cash Conversion
PBYI
PBYI
WEYS
WEYS
Q4 25
2.76×
Q3 25
1.10×
-0.17×
Q2 25
2.41×
4.53×
Q1 25
1.21×
0.74×
Q4 24
2.04×
Q3 24
0.54×
-0.05×
Q2 24
0.59×
Q1 24
2.16×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PBYI
PBYI

Segment breakdown not available.

WEYS
WEYS

Wholesale$56.7M74%
Retail Segment$13.3M17%
Other$6.8M9%

Related Comparisons